论文部分内容阅读
目的 获得大量人源化抗人活化血小板单抗SZ5 1Hu和尿激酶原 (scuPA)融合蛋白SZ5 1Hu scuPA并测定该基因重组抗体导向溶栓剂的导向溶栓性。方法 通过转瓶扩大培养系统获得大量SZ5 1Hu scuPA ;通过抗体竞争结合实验证明融合蛋白的抗体亲和力 ;进而与尿激酶进行比较对不同浓度血小板血浆凝块的溶栓研究。结果 该融合蛋白在培养上清中的表达量为 5mg/ml;其纤溶活性为 390 0 0IU/mg ;抗体亲和力是鼠源性单抗的 6 7% ;体外溶栓效力较uPA提高 4 1～ 8 4倍。结论 该融合蛋白比uPA具有更高、更快的溶栓效率 ,是一种高效抗体导向溶栓剂
Objective To obtain a large number of humanized anti-human activated platelet monoclonal antibody SZ5 1Hu and urokinase (scuPA) fusion protein SZ5 1Hu scuPA and determine the gene-directed recombinant thrombolytic agent-induced thrombolysis. Methods A large number of SZ5 1Hu scuPA was obtained by expanding flask culture system. The antibody affinity of the fusion protein was confirmed by the antibody binding assay. The thrombolytic activity of fusion protein was also compared with urokinase. Results The fusion protein was 5 mg / ml in culture supernatant and its fibrinolytic activity was 390 0 0 IU / mg. The affinity of the fusion protein was 67% of that of murine monoclonal antibody. The in vitro thrombolytic potency was 4 1 ~ 8 4 times. Conclusion The fusion protein has a higher and faster thrombolytic efficiency than uPA and is an efficient antibody-guided thrombolytic agent